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Abstract
Background Shigella is one of the most common causes of childhood dysentery along with high rate of morbidity and mortal-
ity in both developing and developed countries. According to the World Health Organization (WHO) reports, the prevalence 
of fluoroquinolones-resistant Shigella species is increasing worldwide which can cause treatment failure of Shigella infec-
tions. Since there has not been any comprehensive information on drug-resistant Shigella species in Iran, we conducted the 
following meta-analysis to raise awareness.
Methods We conducted a literature search on antibiotic resistance of Shigella species to collect published studies in Iran 
using national and international databases. Literature search was performed by up to Jan 30, 2019 and eligible studies were 
included in the meta-analysis by predefined criteria.
Results Antimicrobial susceptibility testing using disk diffusion technique was the only used method in all included studies. 
Antibiotic resistance characteristics of Shigella species against WHO recommended therapeutic regimens were as follows: S. 
dysenteriae 7%, S. flexneri 3.8%, S. boydii 6.9% and S. sonnei 2.6% to ciprofloxacin, S. dysenteriae 27.9%, S. flexneri 19.3%, 
S. boydii 15.7% and S. sonnei 9.5% to ceftriaxone and also S. dysenteriae 91.7%, S. flexneri 20.7%, S. boydii 46.7% and S. 
sonnei 32.3% to azithromycin. Resistance to pivmecillinam has not been investigated in Iran.
Conclusions Our findings revealed that ciprofloxacin can still be used as the first-line antibiotic for Shigella infections in 
Iranian children. However, it seems that second-line antibiotics i.e., ceftriaxone and azithromycin are not good choices for 
treatment and thus not recommended.
Keywords Antibiotic resistance · Fluoroquinolone · Iran · Shigella
Introduction
The genus Shigella includes non-motile, non-encapsulated, 
Gram-negative, oxidase negative and facultative anaerobic 
rods which belong to the family Enterobacteriaceae and tribe 
Escherichieae [1]. These intracellular pathogens are grouped 
into four species based on biochemical and serological prop-
erties including S. dysenteriae (group A), S. flexneri (group 
B), S. boydii (group C) and S. sonnei (group D) [1]. Shigella 
species are the causative agents for acute shigellosis only in 
humans, which is characterized by fever, diarrhoea (watery 
or bloody), abdominal pain and tenesmus (rectal spasms), 
and abundant leukocytes, blood and mucus in the stool [1–3]. 
According to the Centers for Disease Control and Prevention 
reports, 80–165 million cases of Shigella infections occur 
each year in the world along with 6,000,000 deaths [1, 2]. 
The most severe form of shigellosis with significant fatality 
rates is associated with S. dysenteriae (epidemic shigellosis) 
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and S. flexneri (endemic shigellosis) [3]. However, relatively 
mild infections are attributed to S. sonnei and S. boydii [3]. 
The prevalence of S. dysenteriae and S. boydii infections is 
rare but S. flexneri and S. sonnei infections are more com-
mon in developing and developed countries, respectively 
[1, 2]. Shigella infection is more common among children 
less than 5 years and is responsible for up to 28% children 
deaths in severe disease in resource-limited settings [1–4]. 
Based on the Global Burden of Disease Consortium report 
in 2015, Shigella-associated diarrhoea was the third cause 
of death in children < 5 years of age [5]. Shigella infection is 
acquired through consuming contaminated food and water, 
the fecal–oral route and person-to-person contact, especially 
in adults during household contacts with infected children 
[1, 2]. In the treatment guideline recommended by the 
World Health Organization (WHO) in 2005, ciprofloxacin 
for 3 days is the first-line treatment of acute bloody diar-
rhoea (dysentery) in children [3]. However, WHO in 2017 
reported increased prevalence of Shigella species resistant to 
fluoroquinolones, thereby necessitating research to find new 
drugs [6]. The second-line treatment which is mainly used 
against ciprofloxacin-resistant Shigella species is pivmecil-
linam (amdinocillin pivoxil) and ceftriaxone for 5 days [3]. 
Additionally, shigellosis in adult patients can be treated with 
azithromycin [3]. Since the overall resistance rate of Shigella 
species to fluoroquinolones is not clear in Iran, the current 
systematic review and meta-analysis was conducted to esti-
mate the prevalence of fluoroquinolones-resistant Shigella 
species as well as other susceptibility patterns in Iran.
Methods
Search strategy and selection criteria
A systematic search was performed in the Scientific Infor-
mation Database (SID) (https ://www.sid.ir/En/Journ al), Pub-
Med, Scopus, Web of Science and Google Scholar to find 
any available evidence published before Jan 30, 2019 on 
the prevalence of antibiotic resistance of Shigella species in 
Iran. Antibiotic resistance, S. dysenteriae, S. flexneri, S. boy-
dii, S. sonnei and Iran were search terms extracted from the 
MeSH database. In the next step, collected articles during 
systematic search were evaluated to select eligible reports 
based on inclusion and exclusion criteria. Studies which met 
the following two inclusion criteria were included in this 
meta-analysis: (1) published articles in Persian or English 
languages reporting the antibiotic resistance of Shigella spe-
cies among children younger than 10 years. Therefore, we 
excluded studies on Shigella species antibiotic resistance 
isolated from adult’s samples, those which investigated the 
drug resistance only in the genus of Shigella, those which 
investigated the prevalence of drug resistance genes, those 
which investigated the drug resistance in other pathogens 
and non-clinical specimens and those which had not enough 
information; and (2) cross-sectional studies which was lim-
ited to Iran. We excluded duplicate data and reports other 
than original studies as well as those which investigated the 
drug resistance in other countries. We repeated again all pro-
cesses in methods and also exactly checked the reference list 
of included articles to prevent missing any related reports. 
The meta-analysis was performed in accordance with the 
PRISMA recommendations [7].
Data collection and analysis
Similar to previous section, search strategy and selection cri-
teria, collecting the data from included studies was done by 
two authors. The main extracted data tabulated in Tables 1, 
2, 3 and 4 exclusively for each bacterium. We extracted data 
on the number of Shigella resistant to different antibiotics 
for each species and the number of isolated bacteria and 
then the prevalence of resistance patterns for each antibiotic 
calculated as percentage (%) and expressed as 95% confi-
dence intervals (95% CIs). If there was heterogeneity among 
included studies (I2 > 25%), we used random-effects models 
to pooling the data on the prevalence of resistance to antibiot-
ics. Methods used for evaluating antimicrobial susceptibility 
of Shigella species, year of the study and location of the study 
were other extracted data. Publication bias was assessed 
using funnel plots. All analysis was done by Comprehensive 
Meta-Analysis software (Biostat, Englewood, NJ).
Results
Description of study
As shown in Fig. 1, a total of 1201 articles in either Persian 
or English languages were collected from SID, PubMed, 
Scopus, Web of Science and Google Scholar databases. The 
titles and abstracts were evaluated based on related keywords 
and after elimination of duplicates, 34 articles in Persian and 
83 articles in English languages were selected for the evalu-
ation of full texts. Of these, 25 reports were potentially eli-
gible and included in the meta-analysis according to prede-
fined inclusion criteria. However, the rest of the articles were 
excluded for being duplicate studies, abstracts of congress 
articles, reporting antibiotic resistance in adults, reporting 
antibiotic resistance only at the genus level or reporting only 
antibiotic resistance genes. In the current study, 11 studies 
assessed antibiotic resistance profiles of S. dysenteriae, 19 
studies assessed antibiotic resistance profiles of S. flexneri, 
11 studies assessed antibiotic resistance profiles of S. boydii 
and 21 studies assessed antibiotic resistance profiles of S. 
sonnei (Tables 1, 2, 3, 4). All specimens were obtained from 
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stool samples and Kirby–Bauer’s disk diffusion method was 
the only technique applied to evaluate antimicrobial suscep-
tibility testing. As presented in Figs. 2, 3, 4 and 5, assess-
ing the prevalence of Shigella species resistant to different 
antibiotics showed some evidence of funnel plot asymmetry 
and publication bias.
Characteristics of S. dysenteriae antibiotic resistance
Antibiotic resistance rates to nucleic acid synthesis inhibitors 
and antimetabolites were as follows: 7% (95% CI 3.3–14.4; 
I2 = 0.0%; P = 0.98) to ciprofloxacin, 0% to ofloxacin, 34.6% 
(95% CI 13.4–64.4; I2 = 74.9%; P = 0.00) to nalidixic acid 
and 75.7% (95% CI 47.2–91.6; I2 = 73.4%; P = 0.00) to tri-
methoprim/sulfamethoxazole. Antibiotic resistance rate to 
cell wall synthesis inhibitors was as follows: 85.7% (95% CI 
35.7–98.5; I2 = 39.8%; P = 0.19) to amoxicillin, 29.8% (95% 
CI 11.3–58.6; I2 = 40.8%; P = 0.19) to amoxicillin/clavulanic 
acid, 54.9% (95% CI 18.2–87; I2 = 83.2%; P = 0.00) to ampi-
cillin, 0% to ampicillin–sulbactam, 20% (95% CI 2.7–69.1; 
I2 = 0.0%; P = 1.0) to imipenem, 100% to cefotaxime, 27.9% 
(95% CI 14.1–47.5; I2 = 40.2%; P = 0.11) to ceftriaxone, 
20.2% (95% CI 4.4–58.1; I2 = 42.7%; P = 0.15) to cefixime, 
16% (95% CI 7.1–32.3; I2 = 0.0%; P = 0.76) to ceftazidime, 
27.7% (95% CI 3.1–82.1; I2 = 75.7%; P = 0.00) to cepha-
lothin, 80% to ceftizoxime and 50% to cephalexin. Antibiotic 
resistance rate to protein synthesis inhibitors was as follows: 
83.1% (95% CI 65.8–92.7; I2 = 29.3%; P = 0.21) to tetracy-
cline, 27.1% (95% CI 10.3–54.7; I2 = 52.1%; P = 0.04) to 
gentamicin, 91.7% (95% CI 37.8–99.5; I2 = 0.0%; P = 1.0) to 
azithromycin, 25% (95% CI 7.2–58.9; I2 = 77.8%; P = 0.00) 
to amikacin, 88% (95% CI 28.1–99.3; I2 = 69.3%; P = 0.07) 
to kanamycin, 30% (95% CI 7.1–70.6; I2 = 84.9%; P = 0.00) 
to chloramphenicol, 75% to erythromycin, 20% to tobramy-
cin and 7.1% to nitrofurantoin.
Characteristics of S. flexneri antibiotic resistance
Antibiotic resistance rates to nucleic acid synthesis inhibitors 
and antimetabolites were as follows: 3.8% (95% CI 1.3–10.6; 
I2 = 72.2%; P = 0.00) to ciprofloxacin, 31.2% to ofloxacin, 
16.6% (95% CI 10.4–25.5; I2 = 83.6%; P = 0.00) to nalidixic 
acid and 83.4% (95% CI 78.6–87.3; I2 = 57.8%; P = 0.00) to 
trimethoprim/sulfamethoxazole. Antibiotic resistance rate to 
cell wall synthesis inhibitors was as follows: 80.5% (95% CI 
28.4–97.7; I2 = 77.9%; P = 0.01) to amoxicillin, 41.3% (95% 
CI 20.6–65.7; I2 = 85.1%; P = 0.01) to amoxicillin/clavu-
lanic acid, 87.2% (95% CI 76.5–93.4; I2 = 89.2%; P = 0.00) 
to ampicillin, 0% to ampicillin–sulbactam, 10.6% (95% CI 
1–57.6; I2 = 64.4%; P = 0.09) to imipenem, 0% to merope-
nem, 42.7% (95% CI 32.1–53.9; I2 = 35.6%; P = 0.21) to 
cefotaxime, 19.3% (95% CI 8.8–37.2; I2 = 91.8%; P = 0.00) 
to ceftriaxone, 25.6% (95% CI 4.7–70.8; I2 = 88.3%; 
P = 0.00) to cefixime, 26.8% (95% CI 11.7–50.3; I2 = 83.6%; 
P = 0.00) to ceftazidime, 32.8% (95% CI 7–76.1; I2 = 90.2%; 
P = 0.00) to cephalothin, 22.6% to ceftizoxime and 8.3% 
to cephalexin. Antibiotic resistance rate to protein syn-
thesis inhibitors was as follows: 83.1% (95% CI 67–92.3; 
I2 = 80.2%; P = 0.00) to tetracycline, 9.9% (95% CI 6.1–15.6; 
I2 = 56.2%; P = 0.00) to gentamicin, 100% to streptomycin, 
20.7% (95% CI 4.2–61.1; I2 = 92.2%; P = 0.00) to azithro-
mycin, 12.3% (95% CI 6–23.4; I2 = 69.7%; P = 0.00) to 
amikacin, 56.1% (95% CI 32.3–77.3; I2 = 81%; P = 0.02) to 
kanamycin, 50.5% (95% CI 27–73.9; I2 = 93.4%; P = 0.00) to 
chloramphenicol, 60% to erythromycin, 27.3% to tobramycin 
and 2.9% to nitrofurantoin.
Characteristics of S. boydii antibiotic resistance
Antibiotic resistance rates to nucleic acid synthesis inhibi-
tors and antimetabolites were as follows: 6.9% (95% CI 
2.6–17.2; I2 = 0.0%; P = 0.96) to ciprofloxacin, 0% to ofloxa-
cin, 23.7% (95% CI 14–37.4; I2 = 1.9%; P = 0.41) to nalidixic 
acid and 70.4% (95% CI 58.5–80.1; I2 = 0.0%; P = 0.71) to 
trimethoprim/sulfamethoxazole. Antibiotic resistance rate 
Fig. 1  The study selection process
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to cell wall synthesis inhibitors was as follows: 66.7% (95% 
CI 15.4–95.7; I2 = 0.0%; P = 1.0) to amoxicillin, 48.5% 
(95% CI 29–68.6; I2 = 35.8%; P = 0.21) to amoxicillin/cla-
vulanic acid, 53.5% (95% CI 41–65.7; I2 = 12.3%; P = 0.33) 
to ampicillin, 0% to ampicillin–sulbactam, 33.3% (95% CI 
4.3–84.6; I2 = 0.0%; P = 1.0) to imipenem, 25% (95% CI 
0.9–92.8; I2 = 74.2%; P = 0.04) to cefotaxime, 15.7% (95% 
CI 8.6–27.1; I2 = 0.0%; P = 0.79) to ceftriaxone, 16.9% (95% 
CI 5.3–42.2; I2 = 0.0%; P = 0.53) to cefixime, 30.4% (95% CI 
8.6–67.1; I2 = 57.6%; P = 0.03) to ceftazidime, 35.6% (95% 
CI 10.6–72.2; I2 = 61.1%; P = 0.05) to cephalothin, 100% 
to ceftizoxime and 0% to cephalexin. Antibiotic resistance 
rate to protein synthesis inhibitors was as follows: 57.8% 
(95% CI 29.6–81.8; I2 = 51.7%; P = 0.08) to tetracycline, 
11.9% (95% CI 4.9–26.1; I2 = 0.0%; P = 0.84) to gentamicin, 
46.7% (95% CI 1.5–98.1; I2 = 73.7%; P = 0.05) to azithromy-
cin, 10.3% (95% CI 3.2–28.3; I2 = 0.0%; P = 0.52) to ami-
kacin, 60.7% (95% CI 22.1–89.4; I2 = 32.5%; P = 0.22) to 
kanamycin, 35.3% (95% CI 9–75; I2 = 78.1%; P = 0.00) to 
chloramphenicol, 84% to erythromycin, 12.5% to tobramycin 
and 0% to nitrofurantoin.
Characteristics of S. sonnei antibiotic resistance
Antibiotic resistance rates to nucleic acid synthesis inhibi-
tors and antimetabolites were as follows: 2.6% (95% CI 
1.5–4.7; I2 = 0.0%; P = 0.69) to ciprofloxacin, 12.5% to 
ofloxacin, 27% (95% CI 14.9–44; I2 = 92.2%; P = 0.00) to 
nalidixic acid and 90.3% (95% CI 82.9–94.7; I2 = 83.7%; 
P = 0.00) to trimethoprim/sulfamethoxazole. Antibiotic 
resistance rate to cell wall synthesis inhibitors was as 
follows: 56.8% (95% CI 22.2–85.9; I2 = 90.4%; P = 0.00) 
to amoxicillin, 30.8% (95% CI 24.1–38.5; I2 = 0.0%; 
P = 0.69) to amoxicillin/clavulanic acid, 64.2% (95% CI 
52.4–74.5; I2 = 88.3%; P = 0.00) to ampicillin, 1.2% to 
ampicillin–sulbactam, 2.3% (95% CI 0.3–14.9; I2 = 0.0%; 
P = 0.38) to imipenem, 0% to meropenem, 16.4% (95% CI 
5.9–38.1; I2 = 87.7%; P = 0.00) to cefotaxime, 9.5% (95% 
Fig. 2  Meta-analyses of the prevalence of S. dysenteriae resistant to ciprofloxacin in Iran. a forest plot, b funnel plot
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CI 3.7–22; I2 = 81.7%; P = 0.00) to ceftriaxone, 19.2% 
(95% CI 1.9–74.4; I2 = 91.8%; P = 0.00) to cefixime, 16.3% 
(95% CI 6.3–36.1; I2 = 87.1%; P = 0.00) to ceftazidime, 
22.4% (95% CI 9.3–44.8; I2 = 88.7%; P = 0.00) to cepha-
lothin, 6.7% to ceftizoxime and 26.6% to cephalexin. Anti-
biotic resistance rate to protein synthesis inhibitors was as 
follows: 78.5% (95% CI 56.2–91.2; I2 = 87.8%; P = 0.00) to 
tetracycline, 5.2% (95% CI 2.2–11.7; I2 = 77.9%; P = 0.00) 
to gentamicin, 97.4% (95% CI 92.3–99.2; I2 = 0.0%; 
P = 0.82) to streptomycin, 32.3% (95% CI 9.3–68.9; 
I2 = 80%; P = 0.00) to azithromycin, 6.7% (95% CI 
2.6–16.6; I2 = 76.6%; P = 0.00) to amikacin, 42.5% (95% 
CI 9.8–83.5; I2 = 88.6%; P = 0.00) to kanamycin, 21.3% 
(95% CI 11.1–37.1; I2 = 82.3%; P = 0.00) to chlorampheni-
col, 75% to erythromycin, 93% to minocycline, 100% to 
clindamycin, 100% to ticarcillin, 27.9% to tobramycin and 
0% to nitrofurantoin.
Discussion
Contrary to Salmonella, which is the causative agent for 
dysentery in industrialized countries, Shigella is the most 
common cause of childhood dysentery along with high mor-
bidity and mortality in developing countries especially in the 
tropical areas such as Iran [33]. Therefore, it is important 
to provide an effective antimicrobial treatment to reduce 
the incidence of dysentery in children through shortening 
the pathogen release time and reducing transmission time 
[34]. WHO recommended ciprofloxacin, as the first-line 
Fig. 3  Meta-analyses of the prevalence of S. flexneri resistant to ciprofloxacin in Iran. a  forest plot, b funnel plot
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antibiotic, and ceftriaxone, pivmecillinam or azithromycin, 
as the second-line antibiotics, in treating dysentery [33]. 
This meta-analysis suggested that the antibiotic resistance 
rate of the four serogroups of Shigella to ciprofloxacin, a 
quinolone, was low including S. dysenteriae 7%, S. flexneri 
3.8%, S. boydii 6.9% and S. sonnei 2.6% (Figs. 2, 3, 4, 5). 
Similar results were reported from Asia, Africa and South 
America [35]. However, antibiotic resistance rate of Shi-
gella species to other quinolones was variable in Iran, i.e., 
nalidixic acid 16.6–34.6% and ofloxacin 0–31.2%. Similar 
resistance rates to nalidixic acid were reported in the area 
of Asia–Africa (33.6%) but it was low in Europe–America 
(3.2%) in during 1998–2009 [36]. In spite of the good ther-
apeutic effects of third-generation cephalosporins against 
shigellosis, in recent decades, resistance to these drugs has 
emerged [34]. In the current study, resistance to the third-
generation cephalosporins, ceftriaxone, cefotaxime and cef-
tazidime, in Iran was different among the four serogroups of 
Shigella. S. dysenteriae (27.9, 100 and 16%, respectively), 
S. flexneri (19.3, 42.7 and 26.8%, respectively) and S. boydii 
(15.7, 25 and 30.4%, respectively) showed higher resistance 
rates compared with S. sonnei (9.5, 16.4 and 16.3%, respec-
tively). In total, the resistance prevalence of Shigella species 
in Iran was higher than those reported from Asia–Africa 
(ceftriaxone 14.2, cefotaxime 22.6 and ceftazidime 6.2%) 
and Europe–America (less than 1%) during 1998–2012 [34]. 
Additionally, the resistance rate of Shigella species to other 
cephalosporins including cefixime, cephalothin, ceftizoxime 
and cephalexin was variable in Iran.
Pathogens’ resistance to pivmecillinam has not been 
investigated in Iran. On the other hand, the emergence 
of the macrolide azithromycin-resistant Shigella species 
has been reported in some areas such as the Southeast 
Asia in which susceptibility to azithromycin is decreased 
[37]. Notably, we also observed a high rate of resist-
ance to azithromycin among Shigella species isolated in 
Iran (S. sonnei 32.3, S. boydii 46.7, S. flexneri 20.7 and 
S. dysenteriae 91.7%). Antimicrobial resistance patterns 
Fig. 4  Meta-analyses of the prevalence of S. boydii resistant to ciprofloxacin in Iran. a forest plot, b funnel plot
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of Shigella species to other widely used and inexpen-
sive drugs in different parts of the world, i.e., tetracy-
cline, ampicillin and trimethoprim/sulfamethoxazole, is 
increasing [36]. Serogroups of Shigella showed different 
tetracycline resistance rate which varies between 0 and 
36% in studies conducted in South America, 53.3–100% 
in Africa and 52–100% in Asia [35]. In Iran, the lowest 
and highest resistance rates to tetracycline were observed 
for S. boydii (57.8%) and S. dysenteriae (83.1%), respec-
tively. Ampicillin resistance rate varies between 9 and 
100% in South America, 37.5 and 95% in Africa and 8 
and 100% in Asia [35]. In Iran, the lowest and highest 
resistance rates to ampicillin were observed for S. boydii 
(53.5%) and S. flexneri (87.2%), respectively. Addition-
ally, trimethoprim/sulfamethoxazole resistance rate var-
ies between 0 and 33% in South America, 0 and 90.8% 
in Africa, and 50 and 100% in Asia [35]. The lowest and 
highest resistance rates to trimethoprim/sulfamethoxazole 
in Iran were observed for S. boydii (70.4%) and S. sonnei 
(90.3%), respectively. Similar to quinolones, increasing 
aminoglycoside-resistant Shigella is evident worldwide 
[36]. In a systematic review and meta-analysis conducted 
during 1999–2010, the prevalence of aminoglycoside-
resistant Shigella was as follows: gentamicin-resistance 
rates: 0.34% in America, 1.59% in Europe, 8.37% in Africa 
and 10.65% in Asia [38], in the current meta-analysis in 
Fig. 5  Meta-analyses of the prevalence of S. sonnei resistant to ciprofloxacin in Iran. a forest plot, b funnel plot
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Iran, the prevalence of gentamicin-resistant Shigella was 
27.1, 9.9, 11.9 and 5.2% for S. dysenteriae, S. flexneri, S. 
boydii and S. sonnei, respectively; kanamycin-resistance 
rates: 0.59% in America, 0.58% in Europe, 8.65% in Africa 
and 16.78% in Asia [38], in the current meta-analysis in 
Iran, the prevalence of kanamycin-resistant Shigella was 
88, 56.1, 60.7 and 42.5% for S. dysenteriae, S. flexneri, S. 
boydii and S. sonnei, respectively; and amikacin-resistance 
rates: 0% in America, 10.69% in Africa and 16.29% in 
Asia [38], in the current meta-analysis in Iran, the preva-
lence of amikacin-resistant Shigella was 25, 12.3, 10.3 
and 6.7% for S. dysenteriae, S. flexneri, S. boydii and S. 
sonnei, respectively. The prevalence of chloramphenicol-
resistant Shigella species varied between 21.3 and 50.5% 
among the four serogroups of Shigella in Iran, while it 
was between 0 and 3.9%, 11 and 90%, and 0 and 94.4% in 
the studies conducted in South America, Africa and Asia, 
respectively [35].
In conclusion, according to the findings of the present 
meta-analysis, the prevalence of ciprofloxacin-resistant Shi-
gella species in Iran is low. Therefore, this antibiotic can still 
be used as the first-line antibiotic for Shigella infections in 
Iranian children. However, other quinolones are not good 
choices for treatment, and thus not recommended. Another 
notable point to mention is the high resistance rate of the 
four serogroups of Shigella isolated from Iranian children 
against second-line antibiotics, i.e., ceftriaxone and azithro-
mycin. Therefore, we do not recommend ceftriaxone and 
azithromycin for the treatment of Shigella infections in Ira-
nian children. Resistance to another second-line antibiotic, 
i.e., pivmecillinam has not been investigated in Iran. We pro-
pose determining the prevalence of pivmecillinam-resistant 
Shigella species in the future studies.
Author contributions FK presented idea, performed systematic search, 
data collection and meta-analysis; AS contributed to perform system-
atic search, to the analysis of the results and to the writing of the manu-
script. All authors approved the final version of the manuscript.
Funding No external funding was secured to conduct this study.
Compliance with ethical standards 
Ethical approval Not needed.
Conflict of interest The authors have no conflict of interest to declare.
References
 1. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 
8th ed. London: Elsevier Health Sciences; 2015. p. 260–1.
 2. Killackey SA, Sorbara MT, Girardin SE. Cellular aspects of 
Shigella pathogenesis: focus on the manipulation of host cell 
processes. Front Cell Infect Microbiol. 2016;6:38.
 3. WHO. The treatment of diarrhoea: a manual for physicians and 
other senior health workers. Geneva: World Health Organiza-
tion; 2005.
 4. Tickell KD, Brander RL, Atlas HE, Pernica JM, Walson JL, Pav-
linac PB. Identification and management of Shigella infection in 
children with diarrhoea: a systematic review and meta-analysis. 
Lancet Glob Health. 2017;5:e1235–48.
 5. GBD Diarrhoeal Diseases Collaborators. Estimates of global, 
regional, and national morbidity, mortality, and aetiologies of 
diarrhoeal diseases: a systematic analysis for the Global Burden 
of Disease Study 2015. Lancet Infect Dis. 2017;17:909–48.
 6. WHO. WHO publishes list of bacteria for which new antibiotics 
are urgently needed. Geneva: WHO; 2017.
 7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, 
Ioannidis JP, et al. The PRISMA statement for reporting system-
atic reviews and meta-analyses of studies that evaluate health 
care interventions: explanation and elaboration. PLoS Med. 
2009;6:e1000100.
 8. Jomezadeh N, Babamoradi S, Kalantar E, Javaherizadeh H. Iso-
lation and antibiotic susceptibility of Shigella species from stool 
samples among hospitalized children in Abadan, Iran. Gastro-
enterol Hepatol Bed Bench. 2014;7:218–23.
 9. Nikfar R, Shamsizadeh A, Darbor M, Khaghani S, Moghaddam 
M. A Study of prevalence of Shigella species and antimicrobial 
resistance patterns in pediatric medical center, Ahvaz, Iran. Iran 
J Microbiol. 2017;9:277–83.
 10. Barak M, Arzanlou M, Babapour B, Ghorbani L. Antibiotic 
resistance pattern of bacterial enteritis among hospitalized 
children in Ardabil: a single center experience. Int J Adv Med. 
2016;3:989–93.
 11. Ebrahimi AA, Ebrahimi S, Aghouli M. Survey of resistance rate 
of Shigella species isolated from children with diarrhea in Fasa, 
Summer, 1383. Iran South Med J. 2009;12:225–30 (in Persian).
 12. Mashouf RY, Moshtaghi AA, Hashemi SH. Epidemiology of 
Shigella species isolated from diarrheal children and draw-
ing their antibiotic resistance pattern. Iran J Clin Infect Dis. 
2006;1:149–55.
 13. Masiha AR, Khoshkholgh Pahlaviani MRM, Isazadeh K. The 
assessment of antimicrobial susceptibility patterns of clinical 
isolates of Shigella spp. from diarrheal specimens of children 
in Iran. J Biol Sci. 2011;4:83–92 (in Persian).
 14. Farshad S, Sheikhi R, Japoni A, Basiri E, Alborzi A. Charac-
terization of Shigella strains in Iran by plasmid profile analy-
sis and PCR amplification of ipa genes. J Clin Microbiol. 
2006;44:2879–83.
 15. Talebreza A, Memariani M, Memariani H, Shirazi MH, Sham-
sabad PE, Bakhtiari M. Prevalence and antibiotic susceptibility 
of Shigella species isolated from pediatric patients in Tehran. 
Arch Pediatr Infect Dis. 2016;4:e32395.
 16. Rostamzad A. Molecular epidemiology of Shigella sonnei iso-
lated from clinical cases in Tehran using RAPD-PCR method. 
Glob Adv Res J Med Med Sci. 2015;4:207–12.
 17. Pourakbari B, Mamishi S, Mashoori N, Mahboobi N, Ashtiani 
MH, Afsharpaiman S, et al. Frequency and antimicrobial suscepti-
bility of Shigella species isolated in Children Medical Center Hos-
pital, Tehran, Iran, 2001–2006. Braz J Infect Dis. 2010;14:153–7.
 18. Jafari F, Hamidian M, Salmanzadeh-Ahrabi S, Bolfion M, 
Kharaziha P, Yaghobi M, et al. Molecular diagnosis and antimi-
crobial resistance pattern of Shigella spp. isolated from patients 
with acute diarrhea in Tehran, Iran. Gastroenterol Hepatol Bed 
Bench. 2008;1:11–7.
World Journal of Pediatrics 
1 3
 19. Sakhaei A, Savari M, Shokoohizadeh L, Hadian M, Ekram A. 
Characterization of Shigella strains by plasmid profile analysis 
and antibiotic susceptibility patterns in a pediatric hospital in 
Ahvaz. Int J Enteric Pathog. 2015;3:1–6.
 20. Khaghani S, Shamsizadeh A, Nikfar R, Hesami A. Shigella 
flexneri: a three-year antimicrobial resistance monitoring of 
isolates in a Children Hospital, Ahvaz, Iran. Iran J Microbiol. 
2014;6:225–9.
 21. Aminshahidi M, Arastehfar A, Pouladfar G, Arman E, Fani F. 
Diarrheagenic Escherichia coli and Shigella with high rate of 
extended-spectrum beta-lactamase production: two predominant 
etiological agents of acute diarrhea in Shiraz, Iran. Microb Drug 
Resist. 2017;23:1037–44.
 22. Soltan Dallal MM, Omidi S, Douraghi M, Ashtiani MT, Yazdi 
MK, Okazi A. Molecular analysis of integrons and antimicrobial 
resistance profile in Shigella spp. isolated from acute pediatric 
diarrhea patients. GMS Hyg Infect Control. 2018;13:Doc02.
 23. Mahmoudi S, Pourakbari B, Moradzadeh M, Eshaghi H, Ramezani 
A, Ashtiani MT, et al. Prevalence and antimicrobial susceptibility 
of Salmonella and Shigella spp. among children with gastroenteri-
tis in an Iranian referral hospital. Microb Pathog. 2017;109:45–8.
 24. Farahani NN, Jazi FM, Nikmanesh B, Asadolahi P, Kalani BS, 
Amirmozafari N. Prevalence and antibiotic susceptibility patterns 
of Salmonella and Shigella species isolated from pediatric diar-
rhea in Tehran. Arch Pediatr Infect Dis. 2018;6:e57328.
 25. Noroozi J, Kazemi B, Hakemi Vala M. Study of isolation and 
determination of antibiotic resistance, plasmid profiles, protein 
bands and phenotypic virulence of Shigella flexneri strains. SJKU. 
2007;11:63–73 (in Persian).
 26. Hajizade N, Daneshjo K. Evaluation of in  vitro antimicro-
bial drug-resistance in Imam Khomini hospital. Iran J Pediatr. 
2003;13:133–40 (in Persian).
 27. Ranjbar R, Mammina C, Pourshafie MR, Soltan-Dallal MM. Char-
acterization of endemic Shigella boydii strains isolated in Iran by 
serotyping, antimicrobial resistance, plasmid profile, ribotyping 
and pulsed-field gel electrophoresis. BMC Res Notes. 2008;1:74.
 28. Dolatshahi Z, Amini K. Survey of tetracycline resistance genes in 
Shigella sonnei isolated from acute pediatric with bacterial diar-
rhea using multiplex PCR method and their antibiotic resistance 
patterns. Zanko J Med Sci. 2016;17:35–44 (in Persian).
 29. Soltan Dallal MM, Eghbal M, Sharafianpour A, Zolfaghari MR, 
Yazdi MK. Prevalence and multiple drug resistance of Shigella 
sonnei isolated from diarrheal stool of children. J Med Bacteriol. 
2015;4:33.
 30. Soltan Dallal MM, Nikmanesh B, Haghi-Ashtiani MT, Okazi A, 
Sharifi Yazdi MK. Serotyping and multiple antibiotic resistance pat-
terns of Shigella Sonnei isolated from diarrhea in Children’s Medical 
Center of Tehran. J Payavard Salamat. 2018;11:560–6 (in Persian).
 31. Afshari N, Bakhshi B, Mahmoudi-Aznaveh A, Fallah F, Rahbar 
M, Rafiei Tabatabaei SR. Investigation of prevalence of Shigella 
sonnei in children with diarrhea admitted to two hospital Emam 
Khomeini and Milad in Tehran in 1391 with antimicrobial sus-
ceptibility of isolates. Iran J Med Microbiol. 2016;10:16–22.
 32. Ranjbar R, Soltan Dallal MM, Talebi M, Pourshafie MR. 
Increased isolation and characterization of Shigella sonnei 
obtained from hospitalized children in Tehran, Iran. J Health 
Popul Nutr. 2008;26:426–30.
 33. Traa BS, Walker CL, Munos M, Black RE. Antibiotics for the 
treatment of dysentery in children. Int J Epidemiol. 2010;39(Suppl 
1):i70–4.
 34. Gu B, Zhou M, Ke X, Pan S, Cao Y, Huang Y, et al. Compari-
son of resistance to third-generation cephalosporins in Shigella 
between Europe–America and Asia–Africa from 1998 to 2012. 
Epidemiol Infect. 2015;143:2687–99.
 35. Kahsay AG, Muthupandian S. A review on Sero diversity and anti-
microbial resistance patterns of Shigella species in Africa, Asia 
and South America, 2001–2014. BMC Res Notes. 2016;9:422.
 36. Gu B, Cao Y, Pan S, Zhuang L, Yu R, Peng Z, et al. Comparison of 
the prevalence and changing resistance to nalidixic acid and cip-
rofloxacin of Shigella between Europe–America and Asia–Africa 
from 1998 to 2009. Int J Antimicrob Agents. 2012;40:9–17.
 37. Darton TC, Tuyen HT, The HC, Newton PN, Dance DAB, Phet-
souvanh R, et al. Azithromycin resistance in Shigella spp. in 
Southeast Asia. Antimicrob Agents Chemother. 2018;62:e01748.
 38. Gu B, Ke X, Pan S, Cao Y, Zhuang L, Yu R, et al. Prevalence 
and trends of aminoglycoside resistance in Shigella worldwide, 
1999–2010. J Biomed Res. 2013;27:103–15.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
